Dual triggers revealed for AMD

Two different types of retinal deposits may contribute to early age-related macular degeneration (AMD), with one of them also being indicative of undetected...

Finally, an affordable end to trichiasis

After more than three years of development and five years wading through regulatory paperwork, a new device to permanently remove ingrown eyelashes (trichiasis...

Improving IOL calculations

Swept-source OCT (SS-OCT) biometer Argos is now available in New Zealand and Australia, achieving higher acquisition rates compared with other optical...

New myopia CLs challenge MiSight

A small Australian study comparing CooperVision’s MiSight myopia-controlling disposable contact lenses and the myopia-control effects of two investigational...

Implant success for dropless PK

Researchers in France found a subconjunctival dexamethasone implant used instead of steroid eye drops was safe, well tolerated and prevented graft rejection...

Polygenic risk influences POAG progression

A multicentre Australian study found high polygenic risk among Europeans was associated with more rapid structural and functional progression in early...

Macular thinning associated with central visual-field loss

A multicentre US study found rapid ganglion cell complex (GCC) thinning in glaucoma patients was associated with faster rates of central visual-field decline.  Researchers...

Promising corneal pipeline

US biotechnology company Trefoil Therapeutics has dosed the first patient in its phase 1 study evaluating TTHX1114, a topical eye drop designed to reduce...

IOLs reduce aphakic kids’ glaucoma risk

Following cataract surgery, aphakic children who received a secondary intraocular lens (IOL) had a lower glaucoma risk than those who did not, according...

Silicone oil closes macular holes

German researchers found closing full-thickness macular holes with heavy silicone oil tamponade in secondary surgery to be safe and efficient.  Led by...

Education, genes increase myopia risk

Researchers have uncovered five genetic variants which increase a person’s myopia risk the longer they stay in school.

Glaukos’ trials update

California-based ophthalmic medical company Glaukos announced promising topline results from its phase 2a first-in-human clinical trial for GLK-301 (iLution),...

1625 articles found

Bottom Banner Advert